Jatoi I
Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Clin Ther. 1997 Jan-Feb;19(1):56-61; discussion 2-3. doi: 10.1016/s0149-2918(97)80072-0.
The hormonal milieu at the time of surgery may influence mortality and disease-free survival in patients with primary breast cancer. Indeed, there is evidence that circulating unopposed estrogen is detrimental and that the presence of circulating progesterone results in an improved disease-free and overall survival rate. Thus patients who receive neoadjuvant progesterone therapy may have a better outcome. A randomized controlled trial in which women with primary breast cancer receive either progesterone or placebo before surgery is urgently needed to confirm this hypothesis.
